GB2239246A - Protein antigen from Mycobacterium tuberculosis - Google Patents
Protein antigen from Mycobacterium tuberculosis Download PDFInfo
- Publication number
- GB2239246A GB2239246A GB9027267A GB9027267A GB2239246A GB 2239246 A GB2239246 A GB 2239246A GB 9027267 A GB9027267 A GB 9027267A GB 9027267 A GB9027267 A GB 9027267A GB 2239246 A GB2239246 A GB 2239246A
- Authority
- GB
- United Kingdom
- Prior art keywords
- protein
- tuberculosis
- human
- dna
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000036639 antigens Human genes 0.000 title description 97
- 108091007433 antigens Proteins 0.000 title description 97
- 241000187479 Mycobacterium tuberculosis Species 0.000 title description 2
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 80
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 238000003745 diagnosis Methods 0.000 claims abstract description 30
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 238000002255 vaccination Methods 0.000 claims abstract description 5
- 239000012634 fragment Substances 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 10
- 239000003298 DNA probe Substances 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 206010036790 Productive cough Diseases 0.000 claims description 7
- 108020004518 RNA Probes Proteins 0.000 claims description 7
- 239000003391 RNA probe Substances 0.000 claims description 7
- 210000004910 pleural fluid Anatomy 0.000 claims description 7
- 210000003802 sputum Anatomy 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 108020003215 DNA Probes Proteins 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 230000006052 T cell proliferation Effects 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003118 sandwich ELISA Methods 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 238000001516 cell proliferation assay Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000405 serological effect Effects 0.000 claims 1
- 101710159910 Movement protein Proteins 0.000 abstract description 22
- 102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 abstract description 22
- 150000001413 amino acids Chemical class 0.000 abstract description 12
- 239000000427 antigen Substances 0.000 description 93
- 235000018102 proteins Nutrition 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 241000304886 Bacilli Species 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000013399 early diagnosis Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000001589 lymphoproliferative effect Effects 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 101710097814 13 kDa protein Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027259 Meningitis tuberculous Diseases 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000829189 Staphylococcus aureus Glutamyl endopeptidase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000022971 Tuberculous meningitis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000011842 forensic investigation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A 17 KDa protein has been isolated from M. tuberculosis (South Indian Isolate -1) and sequenced. This 131 amino acid protein and fragments thereof including amino acids 68-77, 91-101 and/or 107-122, antibodies to the protein and the fragments and DNA encoding the protein or fragments, or DNA hybridisable to such DNA are of interest in the immuno diagnosis, therapy and vaccination in relation to human tuberculosis.
Description
"NEW METHODS FOR DIAGNOSIS OF TUBERCULOSIS"
NEW METHODS FOR DIAGNOSIS OF TUBERCULOSIS 1. Summary of the invention
Disclosed are the immunochemical properties of a 17 kDa
protein antigen fractionated, purified and sequenced for
amino acids from Mscobacterium tuberculosis (South Indian
isolate, SII 1) which causes human tuberculosis worldwide
among 16 million patients. The 17 kDa protein antigen which
has an N-terminus of A T T L P V Q R (aa 1-8) has atleast
three specific antibody binding epitopes located on linear
peptides of sequences, R A T Y D K R Y E V R (aa 91-101) and
S E F A Y G S F V R (aa 68-77) which were useful in a micro
ELISA for the early diagnosis of human tuberculosis by the
detection of specific antibodies.The 17 kDa protein antigen
which was mitogenic for human tuberculous peripheral blood
lymphocytes was found to carry three predicted T-cell
epitopes on linear peptides of sequences1 S E F A Y G S F V R
(aa 68-77) and A E L P G V D P D C D V C I T R (aa 107-122).
The 17 kDa antigen of M. tuberculosis (SII 1) which thus had
both B and T cell reactive properties was found to contain
131 amino acids and potentially applicable in the immuno
diagnosis, immuno therapy and immuno prophylaxis bf human
tuberculosis.
2. Field of invention
The present invention relates to a novel 17 kDa protein antigen of Mycobacterium tuberculosis (South Indian Isolate SII 1) and certain peptide fragments derived therefrom, and to the use of the said antigen, and of the peptide fragments derived therefrom, in immuno diagnosis, immunotherapy and immuno prophylaxis of human and experimental tuberculosis.
The invention also relates to the DNA sequence coding for the said 17 kDa antigen, to DNA sequences coding for the said peptide fragments derived from the 17 kDa antigen and to the
DNA and RNA probes constructed on the basis of the protein sequence of the 17 kDa antigen including the sequences of the peptide fragments of the 17 kDa antigen. A major field of use is the use of 17 kDa antigen and peptide fragments thereof in immuno diagnosis of tuberculosis. A further field of use is the use of the 17 kDa antigen or of the said peptide sub structures thereof for the preparation of a vaccine against tuberculosis. A further field of use is the use of the 17 kDa antigen or its sub structure peptides for the detection of T cell proliferation by skin tests or invitro tests in man.This last mentioned field of use is of importance in the possible treatment of human cancer by the boosting of cellular immunity. A further field of use is the use of the 17 kDa antigen or its sub structure peptides for the laboratory production of cellular growth factors and enzymes.
3. Background of invention Human tuberculosis caused by M.tuberculosis is is an important chronic debilitating disease occuring worldwide affecting about 16 million people. While it is prevalent mostly in under developed and developing countries, the recent epidemic of Acquired Immuno Deficiency Syndrome (AIDS) among developed countries has posed a problem of secondary infection with mycobacteria including M. tuberculosis.
Precise and confirmative diagnosis of human TB enables early treatment for which powerful antibiotics are available, although in many countries drug resistance has become a problem. Nevertheless, early diagnosis of TB means effective chemotherapy and thus elimination of the transmission of live bacilli from pulmonary TB patients.
Conventional diagnosis of TB depends upon the clinical and radiological findings, microscopy of tuberculous specimen for bacilli, and bacteriological isolation in culture of ~tuberculosis.
Global control of TB has not yet been established because of the inadequacy of the presently available methods of diaynosis.
Thus many clinical features of TB are not specific to TB alone and a study in India (source: National Tuberculosis
Insitutute, Bangalore, India) revealed that only 30% of the
X-ray suspects eventually developed TB although, in many countries including India, all X-raysuspects are put on anti tuberculous chemotherapy.
The microscopy of tuberculous specimen is not easy under field conditions and atleast 104bacilli/ml are required for effective screening. Many tuberculous specimens like cerebro spinal fluids from tuberculous meningitis infrequently contain bacilli. Further, bacteriological culture generally takes 6 to 8 weeks and is expensive as a routine diagnostic measure.
The widely used tuberculin skin test lacks sensitivity and specificity and takes about 3 days for completion. Since chemotherapy of TB requires compliance for atleast 6 months, many patients who are irregular in treatment develop drug resistance and transmit live bacilli. Finally, the traditional BCG vaccination has now been found to give varying levels of protection depending upon geographic regions.
Consequent to these factors, many investigators including the
WHO recommend that early diagnosis of TB should be considered as a priority area of research and development.
Mycobacteria are powerful immunogens for man and animals, as evidenced by their use in immuno adjuvants to boost immune responses. Thus, many antigens derived from M.tuberculosis have been known to induce the formation of specific antibodies and proliferative lymphocytes among TB patients (Ivanyi et al., 1988) and experimental animal models. The detection of an antibody response in TB has a potential application in early diagnosis. Likewise, the study of
M.tuberculosis specific T lymphocytes has application in early diagnosis by skin tests and development of protective vaccines.
Thus the focus of research in TB pertaining to these aspects lies in the identification and synthesis of M.tuberculosis specific antigens.
4. Prior Art
Many investigators have identified protein antigens of
M.tuberculosis which have potential immuno diagnostic or immuno prophylatic application. The N-terminal and internal amino acid sequences of many of these antigens have been published. The N-terminal amino acid sequences of some of these are presented in Table 1.
Table I: M.tuberculosis protein antigens identified
by N-terminal amino acid sequences.
Investigators Antigens and N-terminus
Investigators Antigens and N-terminus Shinnick et al, 1987 65 kDa: R G C R H P V
Yamaguchi et al, 1987 MPB 57: M A K F N I K P L
Pattorroyo et al, 1987 13 kDa: A K V N I
18 kDa: G D L V G P G A E
23 kDa: A P K T Y
30 kDa: F S X P G L
68 kDa: W M T M T
77 kDa: G K X I A Y D G A A
Matsuo et al, 1988 30 kDa: F S R P G L P
Ashbridge et al, 1989 19 kDa: E H R V K R G L T V
Baird et al, 1989 10 kDa: A K V N I P K P
Garcia et al, 1989 70 kDa: F Q RI T R Q D L L
Borremans et al, 1989 32 kDa: F S R P G L P
To our knowledge, none of these antigens have been introduced as immuno diagnostic test products. Two of these antigens (10 kDa of Baird et al, 1989 and a homologue of 65 kDa antigen of Shinnick et al, 1987) have been tested for vaccine potency among experimental animal models where they showed poor protection against M.tuberculosis (D.W. Smith,
University of Wisconsin, USA, personal communication).
An ELISA kit for diagnosing TB using A60 antigen present in all mycobacteria has been introduced by ANDA diagnostics (France). The test is thus not specific for human TB alone.
An alternative method of diagnosis of TB has been the use of
DNA probes. The commercially available GEN PROBE kit (1988) is used to confirm the identity of members of M.tuberculosis complex isolated in culture and has not been used directly on clinical specimen. A positive result with this test does not rule out other mycobacteria. The DNA probe devised by Enzo
Biochem (J.Clin Microbiol.1988, Dec) used specific DNA sequences of 1000 bases or more in length and claimed to be more specific. A major handicap of all DNA based probes is that whether a true positive reaction can be obtained with specimens of patients so as to avoid the laborious culture of bacilli.
Phenotypic variation in virulence is known among the M.tuberculosis strains isolated in South India (Naganathan et al 1987), the molecular basis for which is not yet established. Abou Zeid et al, (1988) found that a 13 kDa protein antigen was present in phage type II virulent
M.tuberculosis and absent in phage tLpe I South Indian low virulent M.tuberculosis. However, the relationship between this antigen and virulence is yet to be investigated in detail.
5. The Invention
A 17 kDa protein antigen was found to be present among the isolates of M.tuberculosis. The immuno chemical features of this antigen are disclosed under this invention.
Thus the present invention relates to: 1. The 17 kDa protein antigen of M.tuberculosis (SII 1) as defined below and certain sub structures (peptides) of 17 kDa protein antigen as defined below.
2. A DNA sequence coding for the 17 kDa antigen from
M.tuberculosis (SII 1).
3. A DNA sequence coding for the sub structures (peptides) of the 17 kDa antigen from M.tuberculosis (SII 1).
4. The use of the said 17 kDa protein or the said sub structures (peptides) for the preparation of monoclonal or polyclonal antisera which react with the said 17 kDa protein antigen or sub structures thereof. The said antibodies can be raised in mammals like mice, rabbits and goats for polyclonals and in mice for monoclonals.
5. The use of the said 17 kDa protein antigen of the said sub structures (peptides) for the detection of antibodies among human and animal specimen for immuno-diagnosis. Detection methods are known in the art one employs such as ELISA, radio immuno assay (RIA) and reverse passive hemagglutination (RPHA).
6. The use of the 17 kDa protein antigen or sub structures (peptides) thereof for the treatment of tuberculosis.
7. The use of the 17 kDa protein antigen or substructures peptides thereof for the preparation of a vaccine against tuberculosis.
8. The use of the 17 kDa antigen or sub structures (peptides) thereof for the preparation of a reagent for the skin test in immuno diagnosis for tuberculosis.
9. DNA or RNA probes constructed on the basis of the protein sequence of the 17 kDa antigen or sub structures (peptides) thereof for diagnosis of tuberculosis. Such probes can be constructed by methods known in the art. Labelling of such probes can be done by known methods such as radioisotope incorporation or by non radio-active labelling use for example, biotin.
10. A method of diagnosis of human tuberculosis by interacting body fluids such as serum, CSF, pleural fluids from a patient to be diagnosed with a monoclonal antibody to the 17 kDa antigen or its sub structures (peptides) as defined in paragraph 3 above.
11. A method for diagnosis of human tuberculosis by interacting a body fluid such as serum from a patient to be diagnosed with a 17 kDa protein as defined in paragraph 5 above.
12. A method of diagnosing human tuberculosis by interacting body fluids such as sputum, serum, CSF and pleural fluids from a patient to be diagnosed with a DNA or RNA probe as defined in paragraph 9 above.
13. A method for in vitro detection of human tuberculosis which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody as defined in paragraph 10 in labelled form.
14. A method for in vitro detection of human tuberculosis, which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody as defined in paragraph 10 in labelled form.
15. A method for in vitro detection of human tuberculosis, which comprises contacting a sample of a body fluid such as sputum, CSF, plental fluid or serum from a patient with a monoclonal antibody as defined in paragraph 10 in labelled form.
16. A kit for performing immuno diagnosis of tuberculosis utilizing a monoclonal antibody to 17 kDa antigen as disclosed in paragraph 3 above.
17. A kit for immuno diagnosis of tuberculosis utilizing 17 kDa antigen or peptide sub structures as disclosed in paragraph 5 above.
18. A kit for diagnosing tuberculosis utilizing a DNA or RNA probes as disclosed in paragraph 9 above.
19. A micro organism expressing a 17 kDa protein or sub structures thereof as disclosed in paragraph 1 above.
20. A vaccine against tuberculosis developed on the basis of the 17 kDa antigen or sub structure peptides thereof as disclosed in paragraph 1 above. Such a vaccine can be a product of genetically engineered organisms such as
Salmonella, Vaccinia virus etc.
The present invention is exemplified by but not limited to the diagnosis, therapy or prophylaxis of diseases, especially diagnosis of M.tuberculosis infection. Epidemiological screening, forensic investigations, determination of food contaminations, public health surveys, preventive medicine, veterinary and agricultural applications with regard to the diagnosis of infectious agents may be covered by this disclosure.
5.1 Fractionation and purification of 17 kDa antigen.
5.1.1 Crude sonicate antigen.
o
M.tuberculosis (SII 1) was cultured at 37 C for 2 weeks in
Kirchner's medium and harvested bacilli were killed in cold
o acetone for 18 h at 4 C. The bacilli were washed thrice with saline and a suspension of 10 mg bacilli in 5 ml saline was sonicated at 40 watts output using a miniprobe of a
Branson sonifier. The sonicate was centrifuged at 20,000 x g for 30 min and the supernatant was estimated for protein 0 content (Lowry's method) prior to freeze storage at -70 C.
5.1.2 Fractionation and purification.
500 ug of crude sonicate was fractionated on 12.5% sodium dodecyl sulfate polyacrylamide gel as described by
Hunkapiller and Lujan (1986). The protein bands were visualized by brief staining with coomassie brilliant blue and the 17 kDa antigen was electroeluted against 0.05 M ammonium bicarbonate with 0.1% SDS followed by electrodialysis against 0.01 M ammonium bicarbonate with 0.02 % SDS.
The eluted protein was then extracted with chloroformmethanol to remove SDS and the precipitate was dried.
The purity of the eluted protein was analysed by subjecting 5 ug of this precipitate to HPLC using Lichrosorb RP 18 column (LKB). A single peak eluted at 45% B and 26 min was found to contain immuno reactive antigen. Fig. 1 shows the HPLC profile of 17 kDa antigen.
5.2 Amino acid sequence analysis of 17 kDa antigen 5.2.1 Peptide mapping of 17 kDa antigen
Tryptic map: 30 ug of 17 kDa protein was digested with TPCK treated trypsin with an enzyme to substrate ratio of 1:50 in 0 0.1 M ammonium bicarbonate buffer, pH 7.8 at 37 C for 5 h. The tryptic digest was fractionated by HPLC on RP 18 column (0.46 x 25 cm) equilibrated with solvent A (0.1% TFA in water) and the peptides were eluted with a gradient of solvent B (70% acetonitrile containing 0.085% TFA) from 0 to 65% in 60 min. The tryptic map is shown in Fig. 2.
V8 protease map: 30 ug of 17 kDa antigen was treated with 0 staphylococcal V8 protease for 48 h in 0.07% ammonia at 37
C. The molar ratio of the enzyme to substrate was 1:25. The various peptides in the enzyme digest were purified on an
HPLC column uder the conditions used for tryptic mapping.
The peptide profile is shown in Fig. 3.
5.2.2 Sequence analysis of 17 kDa antigen
The amino acid sequence analysis of the protein and the peptide was done using protein sequencer model 477A (Applied
Biosystems Inc., USA) with an on line PTH amino acid analyser. The sample was solubilized in 10% formic acid and fixed onto a polybrene coated (1 mg) TFA treated glass fibre disc and used for sequencing.
The first 18 amino acids from the N-terminal was determined using the whole protein. Based on the amino acid sequences of the tryptic peptides, V8 protease was selected to generate the peptides that could give the overlaps for the tryptic peptides. The alignment of both tryptic and V8 protease peptides gave the complete sequence for the 17 kDa antigen.
The details of the overlaps are given in Fig. 4.
5.2.3 Amino acid composition of 17 kDa antigen
The protein has A9, C3, D11, E10, F9, G8, H2, 17, K4, Lull, M2, P9, Q2, R12, S8, T9, V11 and Y4. It is significant in not having tryptophan and asparagine. The protein is acidic in nature since it has 5 acidic amino acids (D+E=21) in excess of the total number of basic amino acids (R+K=16).
The protein has 131 amino acids that account for a molecular weight of 14,762.
5.3 Immuno reactivity of 17 kDa antigen 5.3.1 Demonstration that 17 kDa antigen is immunodominant in M.tuberculosis strains.
M.tuberculosis (SII 1), M.tuberculosis ATCC 27294, M.phlei, M.
smegmatis, M.kanasasii, M.avium intracellulare and
M.scrofulaceum were cultured in Kirchner's medium for 2 weeks and harvested bacilli were killed in cold acetone. Sonicate antigens were prepared from each of these species as described in section 5.1.1. SDS PAGE analysis of these antigens was then carried out in 12.5% el. Coomassie blue stained gels showed that the 17 kDa antigen was present only in M.tuberculosis strains. A rabbit antiserum raised to
M.tuberculosis SII 1 was also used to probe these sonicates in Western blotting. The dominant 17 kDa band was found in the Western blot.
5.3.2 Demonstration that 17 kDa elicits antibodies among experimental animals.
Electro eluted 17 kDa antigen (10 ug in 100 ul saline) was emulsified with an equal volume of Freund's incomplete adjuvant (FICA) and used for intra peritoneal immunization of 10 BALB/c mice. Serum collected from these mice 30 days after immunization recognized a 17 kDa band in the sonicate antigen of M.tuberculosis SII 1.
Thus this experiment confirms that a polyclonal or monoclonal antibody can be produced in the mouse which recognize the protein structure of 17 kDa antigen or sub structures (peptides) thereof. Such antibodies, in particular the monoclonal antibodies can be used in an antigen detection method like the sandwich ELISA for the detection of the 17 kDa antigen or sub structures thereof among human tuberculosis specimen leading to immuno diagnosis of tuberculosis.
5.3.3 Demonstration that 17 kDa antigen reacts with human TB patient sera.
Sera derived from 24 healthy persons and 20 culture proven TB patients were titrated against the 17 kDa antigen as follows.
PVC Dynatech plates were coated with 1 ug/ml PBS of electro
o eluted 17 kDa antigen for 24 h at 22 C. PBS-BSA blocked plates were then titrated against duplicate (1/200) dilutions
o of sera which were incubated at 22 C for 2.5 h. Washed plates received anti human IgG HRP conjugate for 1.5 h.
Washed plates were then assayed with O-phenylene diamine substrate and read at 492 nm. Table II shows that the 17 kDa antigen had a sensitivity of 70% and specificity of 85%
Table II. Micro ELISA with 17 kDa antigen on sera from TB patients and controls
Serum groups n ELISA + ELISA- Sensitivity Specifici
Healthy people 24 4 20 -- 85%
TB patients 20 14 6 70% -
Sensitivity: Known positivity among TB patients
Specificity: Known negativity among healthy controls
ELISA + : GD 492 nm > =0.3 at 1/200 dilution (=mean + 2SD of
OD 492 nm for healthy controls, n=24].
Thus this experiment confirms that the 17 kDa antigen from M.tuberculosix strains can be used in a micro ELISA system for the immuno diagnosis of tuberculosis in man.
5.3.4 Demonstration that the 17-kDa protein antigen has defined antibody epitopes
The peptide fragments derived from the 17 kDa antigen by tryptic digestion (section 5.2.1, Fig.2) were individually titrated against sera from healthy persons and TB patients as in section 5.3.3. Of the 14 peptides tested, peptides with the sequences RATYDK, YEVR, LEDEMK, UZ, DFDGR and SEFAYGSFVR showed antibody binding activity with sensitivity levels between 17 to 36%. To determine whether these peptides formed linear or conformational antibody epitopes, an inhibition of ELISA was carried out in which each of the peptide was assayed against the other five using the mouse antiserum to 17 kDa antibody.The peptides YEVR and ATYDK were mutually inhibitive thus indicating that they were a part of a complete antibody epitope, which was confirmed also by the determination of the complete structure of the 17 kDa antigen as in section 5.2.2, Fig 4. The other four peptides were linear and probably conformational in the presentation of the antibody epitope. Of the said six antibody epitope bearing peptides, the peptides of the following amino acid sequences were synthesized by solid phase method of
Merrifield and were found to contain specific and sensitive antibody binding activities
RATYDKRYEVR : Sensitivity 65%; Specificity 95%
SEFAYGSFVR : Sensitivity 66%; Specificity 95%
The antibody epitope mapping as described has thus indicated that defined sub structures or peptides of 17 kDa antigen can be synthesized and used for the immunodiagnosis of human tuberculosis in micro ELISA.
5.3.5 Demonstration that 17 kDa antigen is lympho proliferative
Peripheral blood lymphocytes (PBL) from healty donors and TB
6 patients were fractionated and 2 x 10 cells were cultured in presence or absence (control) of 1 ug of 17 kDa antigen for 3 days in RPM1 1640 medium with 10% autologous serum. 24 h before harvesting cultures were pulsed with 1 uCi of 3H thymidine. Table III shows that the 17 kDa antigen was lympho proliferative to the lymphocytes of TB patients (data shown for 2 persons only).
Table III. Lympho proliferative assay with 17 kDa antigen.
Source (PBL) 3H thymidine incorporation (cpm, mean of
triplicate cultures)
Healthy Control : 90 Antigen : 121
TB patient Control : 110 Antigen : 650
In addition to the lympho proliferative property of the 17 kDa antigen, a method of prediction of T cell stimulatory epitopes (Rothbard and Taylor, 1988) was used to map the probable sites in the structure of the 17 kDa antigen. These
T cell epitopes were located on peptides of the following sequences:
SEFAYGSFVR
AELPGVDPDCDVCITR
Thus this experiment indicates that the 17 kDa antigen or sub structures (peptides) can be used to stimulate human peripheral blood lymphocytes.Since stimulated lymphocytes elaborate several cellular growth and differentiation factors which contribute to the vaccine effect of 17 kDa antigen or its sub structures, the 17 kDa antigen can be used at the first instance as a vaccine against TB and also for nonspecifically boosting cellular immunity.
Figure 6 shows the primary structure of the 17 kDa antigen from M.tuberculosis containing the biologically active regions, although similar activity need not be ruled out in the unmarked regions.
6. Discussion and summary of test results
The present invention describes the immunochemical properties of a novel 17 kDa protein antigen from M.tuberculosis (SII 1 strain). M.tuberculosis causes tuberculosis worldwide among 16 million people. Because of inadequacy of the diagnostic procedures available now the disease has not yet been eradicated. The focus of research in recent years has been the development of immuno diagnostic methods for detecting TB at an early stage as well identification of suitable candidates for vaccination since the traditional BCG vaccine has given only a partial protection against TB.
The studies described in this invention show that a novel 17 kDa antigen derived from M.tuberculosis has -antigenic activity. Firstly, it was found to be unique for the South
Indian strains of M.tuberculosis. Secondly, its antigenic nature and chemistry were investigated. Thirdly, the biologically active proteins of the protein antigen were mapped and immuno diagnostic methods were developed for the early detection of TB.
Thus the 17 kDa protein antigen which had 131 amino acids was found to contain two peptides of sequence RATYDKRYEVR and
SEFAYGSFVR which carried antibody binding epitopes for diagnosis of TB. Further, it contained two peptides which carried predicted T cell stimulating regions in sequences,
SEFAYGSFVR and AELPGVDPDCDVCITR. The latter two peptides presumably contributed to the T cell stimulating property of the whole 17 kDa antigen described in this invention. The T cell stimulating property of the 17 kDa antigen and its sub structure peptides means that they could be used in therapy and vaccination for TB.
7. Figure legends.
Fig. 1. HPLC analysis of the electro eluted 17 kDa protein antigen from M. tuberculosis (SII 1).
HPLC conditions: RP 18 column (LKB, 10 um pore size), A: 0.1%
TFA in water, B: 0.085% TFA in 70% aceto nitrile, Gradient: 0 to 65% B in 40 min, Sensitivity: 0.08,220 nm.
Fig. 2. Tryptic peptides of 17 kDa protein antigen from
M.tuberculosis (SII 1) fractionated by HPLC on RP 18 (LKB,10 um pore size).
Fractionation: A: 0.1% TFA in water, B: 0.085% TFA in 70% aceto nitrile, Gradient: 0 to 65% B in 60 min, Sensitivity: 0.08, 220 nm.
Amino acid sequence: Sequence determined are drawn against each peptide.
Fig. 3. V8 protease peptides of 17 kDa protein antigen from
M.tuberculosis (SII 1) fractionated by HPLC on RP 18 (LKB, pore size 10 um).
Fractionation: A: 0.1% TFA in water; B: 0.0858 TFA in 70% aceto nitrile, Gradient: 0 to 65% in 60 min, Sensitivity: 0.082,220 nm.
Fig. 4. The primary structure of the 17 kDa antigen of
M.tuberculosis (SII 1) showing the alignment of peptides. Trp:
Trypsin, V8: Staphylococcus aureus V8 protease. Superscript arrows denote the amino acid sequence obtained with the whole protein.
(Single letter code used for amino acids).
Fig. 5. The primary structure of the 17kDa antigen from
M.tuberculosis (SII 1) showing the biologically active regions.
AA 68 to 77: Antibody and T cell epitopes present.
AA 91 to 101: Antibody epitope present.
AA 107 to 122: Two T cell epitopes present.
8. References 1. A.Hopps and E.J. Woods, Proc.Natl.Acad.Sciences, (1981)
78,3429 2. Hunkapiller, M,W and Lujan E, In, Methods in Protein
Microcharacterization, Ed.J.E. Shiveley, Humana Press
(1986) pp.89 3. Naganathan, N, etal. Tubercle (1986) 67,261 4. Shinnick,F, et al, J.Bacteriol, (1987) 169,1080 5. Yamaguchi, Y, etal, FEBS Letters, (1987) 240,115 6. Pattorroyo G, et al, Modern Biotechnology in Health,
Academic press, (1987), pp.110.
7. Ivanyi, J et al, Springers Seminars Immunopathol,
(1988)10 279 8. Abou-Zeid etal, J.Gen Microbiol (1988) 134,531 9. Matsuo M etal, J.Bacteriol, (1988) 170, 3847 10. Rothbard, J,B and Taylor, , EMBO J (1988) 7,93 11. Ashbridge S, etal, Nucleic Acids Res (1989) 17,1249 12. Boremans et al, Infection and Immunity, (1989) 57, 3123 13. Garcia E, etal (1989) Infection and Immunity
(1989),57,204 14. Baird et al, J.Gen Microbiol, (1989)135, 931.
Claims (33)
1. The protein of the structure: 1 40 ATTLPVQRHPRS LFPEFSELFAAFPSFAGLRPTFDTRELM 80 RSIQITIKLEDEMKGIYLPVAKHGBLRSEFAYGSFVRTVS 131 LPVGADEDDIRATYDKRYEVRDFDGRAELPGVDPDCDVCITRGI LTVSVCV
2. Peptides of the structure:
SEFAYGSFVR
RATYDKRYEVR
AELPGVDPDCDVCITR and fragments of the protein according to claim 1 which include one or more of these peptide sequences.
3. A DNA sequence coding for the protein defined in claim 1.
4. A DNA sequence coding for peptides defined in claim 2.
5. A DNA or RNA hybridization probe, constructed on the basis of the proteins or peptides defined in claim 1 or 2 or on the basis of DNA sequences according to claim 3 or 4, said probe being optionally labelled.
6. An antibody to a protein or peptide as defined in claim 1 or 2.
7. An antibody according to claim 6 which is a polyclonal or a monoclonal antibody, said antibody being optionally labelled.
8. A kit for performing immuno diagnosis of tuberculosis including a protein or peptide according to claim 1 or 2.
9. A kit for performing immuno diagnosis of tuberculosis including a monoclonal antibody according to claim 7.
10. A kit for performing DNA based diagnosis of tuberculosis including a hybridization probe according to claim 5.
11. A microorganism capable of expressing a protein or peptide according to claim 1 or 2.
12. A vaccine against tuberculosis including a protein or peptide according to claim 1 or 2.
13. An in vitro method of diagnosis of human tuberculosis which comprises interacting body fluids such as serum from a patient with a protein or peptide according to claim 1 or 2.
14. An on vitro method of diagnosis of human tuberculosis which comprises interacting body fluids such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody according to claim 7 in labelled form.
15. An in vitro method of diagnosis of human tuberculosis which comprises interacting body fluids such as sputum, CSF, pleural fluid or serum from a patient with a DNA probe according to claim 5 in labelled form.
16. An in vitro method for detection of human tuberculosis, which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a polyclonal antibody according to claim 7 in labelled form.
17. A protein or peptide according to claim 1 or 2 for use in a method of treatment of the human or animal body in immuno-diagnosis, therapy or vaccination in relation to human tuberculosis.
18. A protein or peptide according to claim 1 or 2 for use in a method of treatment of the human or animal body for producing mammalian polyclonal antibodies or monoclonal antibodies in mice for use in an immunodiagnostic method like sandwich ELISA which detects the protein according to claim 1 among human tuberculous specimens.
19. A protein or peptide according to claim 1 or 2 for use in a method of treatment of the human or animal body for the detection of antibodies among tuberculous specimens by serological methods for early detection of tuberculosis.
20. A protein or peptide according to claim 1 or 2 for use in a method of treatment of the human or animal body for the detection of T cell proliferation in a tuberculous specimen for obtaining immuno diagnosis through skin tests or obtaining a candidate for vaccine against tuberculosis.
21. Use of a protein or peptide according to claim 1 or 2 for developing a reagent for therapy of tuberculous inflammation by T cell proliferation.
22. Use of a protein or peptide according to claim 1 or 2 for the production of growth and differentiation factors using T cell proliferation assay.
23. The use of DNA or RNA probes according to claim 5 for detection of M.tuberculosis DNA among human tuberculous specimen for early detection of tuberculosis.
24. The use of DNA or RNA probes according to claim 5 for the purposes of identification of mycobacterial
DNA for example among cultural isolates and for laboratory research.
25. A protein or peptide according to claim 1 or 2 substantially as hereinbefore described.
26. A DNA sequence or a DNA or RNA probe according to any one of claims 3 to 5 substantially as hereinbefore described.
27. An antibody according to claim 6 or 7 substantially as hereinbefore described.
28. A kit according to any one of claims 8 to 10 substantially as hereinbefore described.
29. A microorganism according to claim 11 substantially as hereinbefore described.
30. A vaccine according to claim 12 substantially as hereinbefore described.
31. A method according to any zone of claims 13 to 16 substantially as hereinbefore described.
32. A protein or peptide according to any one of claims 17 to 20 substantially as hereinbefore described.
33. A use according to any one of claims 21 to 24 substantially as hereinbefore described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN938MA1989 IN172697B (en) | 1989-12-22 | 1989-12-22 | |
| SE9001105A SE9001105D0 (en) | 1990-03-27 | 1990-03-27 | NEW METHODS FOR DIAGNOSIS OR TUBERCULOSIS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB9027267D0 GB9027267D0 (en) | 1991-02-06 |
| GB2239246A true GB2239246A (en) | 1991-06-26 |
Family
ID=26324849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9027267A Withdrawn GB2239246A (en) | 1989-12-22 | 1990-12-17 | Protein antigen from Mycobacterium tuberculosis |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU6807390A (en) |
| CA (1) | CA2033042A1 (en) |
| GB (1) | GB2239246A (en) |
| IE (1) | IE904536A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014118A1 (en) * | 1992-01-17 | 1993-07-22 | Medical Research Council | Peptide fragments of hsp71 of m. tuberculosis and their use in diagnosis of tuberculosis |
| WO1996005223A1 (en) * | 1994-08-12 | 1996-02-22 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
| US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
| US6761894B1 (en) | 1993-11-23 | 2004-07-13 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| WO2012035558A3 (en) * | 2010-09-14 | 2012-05-31 | Council Of Scientific & Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
-
1990
- 1990-12-17 GB GB9027267A patent/GB2239246A/en not_active Withdrawn
- 1990-12-17 IE IE453690A patent/IE904536A1/en unknown
- 1990-12-17 AU AU68073/90A patent/AU6807390A/en not_active Abandoned
- 1990-12-21 CA CA002033042A patent/CA2033042A1/en not_active Abandoned
Non-Patent Citations (5)
| Title |
|---|
| Infect. Immun. 1989, 57(10), 3123-3130 * |
| Infect. Immun. 1989, 57(8), 2481-2488 * |
| J. Bacteriol. 1987, 169(3), 1080-1088 * |
| J. Gen. Microbiol. 1989, 135, 931-939 * |
| Nucleic Acids Res. 1989, 17(3), 1249 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014118A1 (en) * | 1992-01-17 | 1993-07-22 | Medical Research Council | Peptide fragments of hsp71 of m. tuberculosis and their use in diagnosis of tuberculosis |
| US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
| US6761894B1 (en) | 1993-11-23 | 2004-07-13 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| WO1996005223A1 (en) * | 1994-08-12 | 1996-02-22 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
| WO2012035558A3 (en) * | 2010-09-14 | 2012-05-31 | Council Of Scientific & Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
| AU2011303430B2 (en) * | 2010-09-14 | 2014-09-11 | Council Of Scientific And Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
| US9340622B2 (en) | 2010-09-14 | 2016-05-17 | Council Of Scientific & Industrial Research | Synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6807390A (en) | 1991-06-27 |
| GB9027267D0 (en) | 1991-02-06 |
| CA2033042A1 (en) | 1991-06-23 |
| IE904536A1 (en) | 1991-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wiker et al. | The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis | |
| Triccas et al. | A 35-kilodalton protein is a major target of the human immune response to Mycobacterium leprae | |
| KR20010012813A (en) | Compounds for diagnosis of tuberculosis and methods for their use | |
| KR19990044347A (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| JPH07508498A (en) | Staphylococcus epidermidis-associated type I and II surface antigens | |
| JP2002503683A (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| JP3747057B2 (en) | Bacterial stress protein | |
| WO1991014448A1 (en) | New proteins, peptides and corresponding dna or rna sequences and probes useful for diagnosing tuberculosis | |
| CN107011418B (en) | Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application thereof | |
| CN107216373B (en) | Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application thereof | |
| Triccas et al. | Molecular and immunological analyses of the Mycobacterium avium homolog of the immunodominant Mycobacterium leprae 35-kilodalton protein | |
| CN107141341B (en) | Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application | |
| US7169393B2 (en) | Antigenic peptide fragments of VapA protein, and uses thereof | |
| GB2239246A (en) | Protein antigen from Mycobacterium tuberculosis | |
| JPH02500403A (en) | Cloning of the 47-kilodalton antigen of Treponema pallidum and its expression | |
| Cimolai et al. | Immunological cross-reactivity of a Mycoplasma pneumoniae membrane-associated protein antigen with Mycoplasma genitalium and Acholeplasma laidlawii | |
| Britton et al. | Dominant cell wall proteins of Mycobacterium leprae recognized by monoclonal antibodies. | |
| JPS61185183A (en) | Hybrid cell system for producing cell lytic monoclonal antibody to vagina trichomonas | |
| AU707298B2 (en) | Broadly reactive opsonic antibodies reactive with common staphylococcal antigens | |
| US7744905B2 (en) | Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses thereof | |
| MX2010009516A (en) | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof. | |
| CN112759644A (en) | Heavy chain and light chain variable region gene of mycobacterium tuberculosis MPT64 protein monoclonal antibody, encoded polypeptide and application thereof | |
| Boiron et al. | Immunodiagnosis of nocardiosis | |
| EP0597110A1 (en) | Method of detecting mesitylene-resistant staphylococcus aureus, novel peptide, and dna coding for same | |
| NZ228529A (en) | Diagnosis of mycobacterium bovis infection in a susceptible animal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |